Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
Ascentage Pharma has announced a clinical collaboration with Acerta Pharma, a part of AstraZeneca (AZN), to sponsor a Phase Ib/II trial studying the combination of Ascentage's APG-2575 (a Bcl-2 inhibitor) and Acerta's CALQUENCE® (acalabrutinib, a BTK inhibitor) for treating relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This multicenter study has begun in the US and will expand to Europe and Australia, targeting efficacy and safety to explore potential synergistic effects and improved treatment options for patients.